IP
LGND icon

Isthmus Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Isthmus Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.62M Sell
20,935
-3,124
-13% -$736K 0.64% 49
2026
Q1 		$4.8M Sell
24,059
-649
-3% -$128K 0.5% 50
2025
Q4 		$4.67M Sell
24,708
-4,790
-16% -$920K 0.52% 53
2025
Q3 		$5.23M Sell
29,498
-7,775
-21% -$1.16M 1.16% 26
2025
Q2 		$4.24M Sell
37,273
-402
-1% -$43K 0.5% 52
2025
Q1 		$3.96M Sell
37,675
-420
-1% -$47.5K 0.5% 49
2024
Q4 		$4.08M Sell
38,095
-459
-1% -$51.9K 0.5% 53
2024
Q3 		$3.86M Sell
38,554
-9,622
-20% -$969K 0.46% 54
2024
Q2 		$4.06M Sell
48,176
-155
-0.3% -$12.3K 0.48% 57
2024
Q1 		$3.53M Buy
48,331
+13,984
+41% +$1.03M 0.4% 72
2023
Q4 		$2.45M Buy
34,347
+1,530
+5% +$90.3K 0.32% 72
2023
Q3 		$1.97M Buy
32,817
+8,026
+32% +$528K 0.28% 74
2023
Q2 		$1.79M Sell
24,791
-103
-0.4% -$7.73K 0.24% 89
2023
Q1 		$1.83M Buy
24,894
+5,064
+26% +$360K 0.26% 85
2022
Q4 		$1.32M Sell
19,830
-12,052
-38% -$784K 0.2% 101
2022
Q3 		$1.71M Buy
31,882
+6,747
+27% +$397K 0.29% 74
2022
Q2 		$1.4M Buy
25,135
+1,539
+7% +$87.3K 0.26% 83
2022
Q1 		$1.66M Buy
23,596
+1,731
+8% +$126K 0.27% 82
2021
Q4 		$2.11M Buy
21,865
+213
+1% +$19.7K 0.35% 64
2021
Q3 		$1.88M Buy
21,652
+93
+0.4% +$7.19K 0.34% 63
2021
Q2 		$1.76M Buy
21,559
+502
+2% +$41.8K 0.31% 77
2021
Q1 		$2M Sell
21,057
-454
-2% -$42.9K 0.37% 59
2020
Q4 		$1.33M Buy
21,511
+2,301
+12% +$131K 0.27% 84
2020
Q3 		$1.14M Buy
19,210
+1,686
+10% +$115K 0.27% 74
2020
Q2 		$1.22M Buy
17,524
+213
+1% +$13.5K 0.3% 64
2020
Q1 		$785K Sell
17,311
-1,040
-6% -$58.9K 0.24% 80
2019
Q4 		$1.19M Buy
18,351
+146
+0.8% +$9.76K 0.27% 80
2019
Q3 		$1.13M Buy
18,205
+2,534
+16% +$159K 0.27% 83
2019
Q2 		$1.12M Buy
+15,671
New +$1.15M 0.27% 78
2019
Q1 		– Sell
-11,056
Closed -$936K – 167
2018
Q4 		$936K Buy
11,056
+1,162
+12% +$124K 0.28% 75
2018
Q3 		$1.69M Sell
9,894
-763
-7% -$115K 0.43% 45
2018
Q2 		$1.38M Sell
10,657
-202
-2% -$22.5K 0.36% 49
2018
Q1 		$1.12M Sell
10,859
-165
-1% -$16.3K 0.3% 56
2017
Q4 		$942K Sell
11,024
-33
-0.3% -$2.86K 0.26% 69
2017
Q3 		$939K Buy
11,057
+33
+0.3% +$2.61K 0.26% 71
2017
Q2 		$835K Sell
11,024
-82
-0.7% -$5.74K 0.24% 76
2017
Q1 		$733K Buy
11,106
+246
+2% +$16.2K 0.22% 85
2016
Q4 		$688K Sell
10,860
-52
-0.5% -$3.28K 0.21% 93
2016
Q3 		$651K Buy
10,912
+98
+0.9% +$7.2K 0.21% 85
2016
Q2 		$805K Sell
10,814
-401
-4% -$29.8K 0.26% 59
2016
Q1 		$749K Buy
11,215
+18
+0.2% +$1.09K 0.25% 64
2015
Q4 		$757K Buy
11,197
+4,897
+78% +$302K 0.26% 65
2015
Q3 		$337K Buy
6,300
+47
+0.8% +$2.85K 0.12% 109
2015
Q2 		$394K Buy
+6,253
New +$341K 0.13% 108

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Isthmus Partners's LGND Position: Q2 2026 in Review

Isthmus Partners reduced its Ligand Pharmaceuticals (LGND) stake by 13% in Q2 2026, selling an estimated $736K and leaving 20,935 shares worth $6.62M. The position accounts for 0.64% of the portfolio, ranked #49.

Isthmus Partners first reported a position in LGND in Q2 2015 and has held it in 44 quarters since. 83 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Isthmus Partners held 20,935 shares of Ligand Pharmaceuticals worth $6.62M as of Q2 2026.
  • Isthmus Partners sold 3,124 Ligand Pharmaceuticals shares in Q2 2026, an estimated $736K.
  • Ligand Pharmaceuticals made up 0.64% of Isthmus Partners's portfolio in Q2 2026, its #49 holding.
  • Isthmus Partners first reported a position in Ligand Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
  • 83 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Isthmus Partners's 13F filing for Q2 2026, filed 20 Jul 2026.